Myelodysplastic Syndromes: Updates and Nuances

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diagnosis, lack of a standard approach with novel agents in MDS, and few prospective long-term, randomized controlled MDS clinical studies to guide allogeneic blood and marrow transplant. With the recent genetic characterization of MDS, certain aspects of these issues will be better addressed by integrating genetic data into clinical study design and clinical practice.

Original languageEnglish (US)
Pages (from-to)333-350
Number of pages18
JournalMedical Clinics of North America
Volume101
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Myelodysplastic Syndromes
Bone Marrow
Genetic Markers
Stem Cells
Transplants
Clinical Studies

Keywords

  • Anemia
  • Azacitidine
  • Blood and marrow transplant
  • Myelodysplastic syndrome
  • Therapy-related myelodysplastic syndrome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Myelodysplastic Syndromes : Updates and Nuances. / Dao, Kim-Hien.

In: Medical Clinics of North America, Vol. 101, No. 2, 01.03.2017, p. 333-350.

Research output: Contribution to journalReview article

@article{7c2e8c2420a94db2933f76a8be2a5744,
title = "Myelodysplastic Syndromes: Updates and Nuances",
abstract = "Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diagnosis, lack of a standard approach with novel agents in MDS, and few prospective long-term, randomized controlled MDS clinical studies to guide allogeneic blood and marrow transplant. With the recent genetic characterization of MDS, certain aspects of these issues will be better addressed by integrating genetic data into clinical study design and clinical practice.",
keywords = "Anemia, Azacitidine, Blood and marrow transplant, Myelodysplastic syndrome, Therapy-related myelodysplastic syndrome",
author = "Kim-Hien Dao",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.mcna.2016.09.006",
language = "English (US)",
volume = "101",
pages = "333--350",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Myelodysplastic Syndromes

T2 - Updates and Nuances

AU - Dao, Kim-Hien

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diagnosis, lack of a standard approach with novel agents in MDS, and few prospective long-term, randomized controlled MDS clinical studies to guide allogeneic blood and marrow transplant. With the recent genetic characterization of MDS, certain aspects of these issues will be better addressed by integrating genetic data into clinical study design and clinical practice.

AB - Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diagnosis, lack of a standard approach with novel agents in MDS, and few prospective long-term, randomized controlled MDS clinical studies to guide allogeneic blood and marrow transplant. With the recent genetic characterization of MDS, certain aspects of these issues will be better addressed by integrating genetic data into clinical study design and clinical practice.

KW - Anemia

KW - Azacitidine

KW - Blood and marrow transplant

KW - Myelodysplastic syndrome

KW - Therapy-related myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85012206664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012206664&partnerID=8YFLogxK

U2 - 10.1016/j.mcna.2016.09.006

DO - 10.1016/j.mcna.2016.09.006

M3 - Review article

C2 - 28189174

AN - SCOPUS:85012206664

VL - 101

SP - 333

EP - 350

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 2

ER -